Meningococcal Vaccine Market Size, Share, and Trends 2024 to 2034

The global meningococcal vaccine market size is calculated at USD 4.02 billion in 2025 and is forecasted to reach around USD 6.63 billion by 2034, accelerating at a CAGR of 5.81% from 2025 to 2034. The North America meningococcal vaccine market size surpassed USD 2.19 billion in 2024 and is expanding at a CAGR of 5.80% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : February 2025
  • Report Code : 4571
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Meningococcal Vaccine Market 

5.1. COVID-19 Landscape: Meningococcal Vaccine Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Meningococcal Vaccine Market, By Type

8.1. Meningococcal Vaccine Market Revenue and Volume, By Type

8.1.1 Polysaccharide Vaccines

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Conjugate Vaccines

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Combination Vaccines

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Other Types

8.1.4.1. Market Revenue and Volume Forecast

Chapter 9. Global Meningococcal Vaccine Market, By End-user

9.1. Meningococcal Vaccine Market Revenue and Volume, By End-user

9.1.1. Children

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Adults

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Meningococcal Vaccine Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Volume Forecast, By Type

10.1.2. Market Revenue and Volume Forecast, By End-user

10.1.3. U.S.

10.1.3.1. Market Revenue and Volume Forecast, By Type

10.1.3.2. Market Revenue and Volume Forecast, By End-user

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Volume Forecast, By Type

10.1.4.2. Market Revenue and Volume Forecast, By End-user

10.2. Europe

10.2.1. Market Revenue and Volume Forecast, By Type

10.2.2. Market Revenue and Volume Forecast, By End-user

10.2.3. UK

10.2.3.1. Market Revenue and Volume Forecast, By Type

10.2.3.2. Market Revenue and Volume Forecast, By End-user

10.2.4. Germany

10.2.4.1. Market Revenue and Volume Forecast, By Type

10.2.4.2. Market Revenue and Volume Forecast, By End-user

10.2.5. France

10.2.5.1. Market Revenue and Volume Forecast, By Type

10.2.5.2. Market Revenue and Volume Forecast, By End-user

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Volume Forecast, By Type

10.2.6.2. Market Revenue and Volume Forecast, By End-user

10.3. APAC

10.3.1. Market Revenue and Volume Forecast, By Type

10.3.2. Market Revenue and Volume Forecast, By End-user

10.3.3. India

10.3.3.1. Market Revenue and Volume Forecast, By Type

10.3.3.2. Market Revenue and Volume Forecast, By End-user

10.3.4. China

10.3.4.1. Market Revenue and Volume Forecast, By Type

10.3.4.2. Market Revenue and Volume Forecast, By End-user

10.3.5. Japan

10.3.5.1. Market Revenue and Volume Forecast, By Type

10.3.5.2. Market Revenue and Volume Forecast, By End-user

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Volume Forecast, By Type

10.3.6.2. Market Revenue and Volume Forecast, By End-user

10.4. MEA

10.4.1. Market Revenue and Volume Forecast, By Type

10.4.2. Market Revenue and Volume Forecast, By End-user

10.4.3. GCC

10.4.3.1. Market Revenue and Volume Forecast, By Type

10.4.3.2. Market Revenue and Volume Forecast, By End-user

10.4.4. North Africa

10.4.4.1. Market Revenue and Volume Forecast, By Type

10.4.4.2. Market Revenue and Volume Forecast, By End-user

10.4.5. South Africa

10.4.5.1. Market Revenue and Volume Forecast, By Type

10.4.5.2. Market Revenue and Volume Forecast, By End-user

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Volume Forecast, By Type

10.4.6.2. Market Revenue and Volume Forecast, By End-user

10.5. Latin America

10.5.1. Market Revenue and Volume Forecast, By Type

10.5.2. Market Revenue and Volume Forecast, By End-user

10.5.3. Brazil

10.5.3.1. Market Revenue and Volume Forecast, By Type

10.5.3.2. Market Revenue and Volume Forecast, By End-user

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Volume Forecast, By Type

10.5.4.2. Market Revenue and Volume Forecast, By End-user

Chapter 11. Company Profiles

11.1. AstraZeneca plc

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Pfizer Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Novartis AG

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Janssen Pharmaceuticals, Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Bharat Biotech International Ltd.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Mitsubishi Tanabe Pharma Corporation

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. GlaxoSmithKline plc

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Sanofi Pasteur

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Merck & Co., Inc.

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Serum Institute of India Pvt. Ltd.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global meningococcal vaccine market size is expected to increase USD 6.63 billion by 2034 from USD 3.77 billion in 2024.

The meningococcal vaccine market is anticipated to grow at a CAGR of over 5.81% between 2025 and 2034

The major players operating in the meningococcal vaccine market are AstraZeneca plc, Pfizer Inc., Novartis AG, Janssen Pharmaceuticals, Inc., Bharat Biotech International Ltd., Mitsubishi Tanabe Pharma Corporation, GlaxoSmithKline plc, Sanofi Pasteur, Merck & Co., Inc., Serum Institute of India Pvt. Ltd., Biomed Pvt. Ltd., Walvax Biotechnology Co., Ltd., Bavarian Nordic A/S, Biological E Limited, Hualan Biological Engineering Inc., Beijing Tiantan Biological Products Corporation Limited., and Others.

The driving factors of the meningococcal vaccine market are the increasing prevalence of meningitis and rising susceptibility of the vulnerable population group.

North America region will lead the global meningococcal vaccine market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client